Targeting Histone H3K9 Methyltransferase G9a as a Potential Therapeutic Strategy for Neuropsychiatric Disorders

Area of Science:

• Neuroscience
• Epigenetics
• Pharmacology

Background:

• Neuropsychiatric disorders involve complex cognitive, social, and motor impairments.
• Epigenetic mechanisms, particularly histone lysine methyltransferases (HKMTs), are increasingly recognized for their role in pathogenesis.
• G9a, a specific HKMT, is a key focus in understanding these disorders.

Purpose of the Study:

• To review the structural and functional aspects of G9a.
• To elucidate G9a's involvement in diverse neuropsychiatric conditions.
• To explore G9a-targeted pharmacological interventions.

Main Methods:

• Literature review of G9a's role in neuropsychiatric disorders.
• Analysis of G9a-mediated biochemical mechanisms.
• Survey of current and potential pharmacological treatments.

Main Results:

• G9a is implicated in neurodevelopmental disorders (NDDs) like ASD and PWS, schizophrenia (SZ), epilepsy, anxiety, depression, and Alzheimer's disease (AD).
• G9a influences disease pathology through specific histone methylation patterns.
• Pharmacological targeting of G9a presents viable therapeutic avenues.

Conclusions:

• G9a is a significant epigenetic regulator in neuropsychiatric disorders.
• Understanding G9a's mechanisms is vital for developing novel treatments.
• G9a represents a key therapeutic target for future research and clinical applications.